Document is current
Any future updates will be listed below
-
Authors
Li, Xiaona
Winters, Nathan D.
Pandey, Shubhi
Lankford, Colten
Stoveken, Hannah M.
Smith, Emery https://orcid.org/0000-0002-9217-6892
Chang, Chu-Ting
Zucca, Stefano
Scampavia, Louis
Spicer, Timothy https://orcid.org/0000-0002-9080-4226
Martemyanov, Kirill A. https://orcid.org/0000-0002-9925-7599
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (DA036596)
- License Information
-
More Information
Article History
Received: 29 April 2024
Accepted: 12 July 2025
First Online: 23 July 2025
Competing interests
: K.A.M. is a consultant and stakeholder in EvoDenovo, Inc. a company commercializing the development of innovative treatments for opioid use disorder. All other authors declare no competing interests.
